From an article by :

We’re seeing a new wave of venture investments in healthtech companies — especially those with strong artifical intelligence and machine learning components. Led by some of the world’s largest biopharma companies and tech-focused venture capitalists, these investments are backing efforts to speed drug discovery, improve tests and treatments, and further medical research. For now, most of the investment is focused in the diagnostics/tools (Dx/Tools) sector.

A Silicon Valley Bank analysis last month found that 44 venture-backed deals raised $2.2 billion between 2015 and the first half of 2017 for Dx/Tools companies that use AI/ML as part of their underlying technology.

Read more at venturebeat.com

Image Credit:   Colorbox

Recent News

Light in a new light

In a paper published in Nature's NPJ Quantum Information ("Multiphoton quantum-state engineering using conditional measurements"), Omar Magaña-Loaiza, assistant professor in the Louisiana State University (LSU) Department of Physics & [...]